Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives

被引:22
作者
Donelan, Ronan [1 ]
Walker, Stuart [2 ]
Salek, Sam [3 ,4 ]
机构
[1] Quintiles, Global Regulatory Affairs, Dublin, Ireland
[2] Ctr Innovat Regulatory Sci, London, England
[3] Univ Hertfordshire, Dept Pharm, Hatfield AL10 9AB, Herts, England
[4] Inst Med Dev, Cardiff, S Glam, Wales
关键词
qualitative; interviews; decision-making; quality; regulatory agencies; pharmaceutical industry; individual; organisation; framework; pharmacoepidemiology; DRUGS;
D O I
10.1002/pds.3752
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PurposeCurrently, there is no qualified understanding of the influences, behaviours and other factors that impact the decision-making of individuals and organisations involved in the development of new medicines. The aim of this qualitative study was to investigate and identify the important issues that influence quality decision-making. MethodsSemi-structured interviews were carried out with 29 senior decision-makers from the pharmaceutical industry and regulatory authorities. The study participants were invited to discuss and review their perception of decision-making within their organisation, its role in drug development and the regulatory review and their awareness and use of decision-making techniques and the impact and monitoring of decisions. ResultsThe analyses (using NVivo 8((c)) software) resulted in the identification of 32 major and 97 sub-themes that were consolidated into 19 overarching themes. These included items such as quality and validity of data, time considerations, organisational and cultural influences, analytical and logical approach, qualification and experience, subjective and personal considerations, political influences, precedents for similar previous decisions, understanding of the decision in question, impact analyses, audit trail, education and awareness, individual versus corporate decision-making and frameworks. Relationships between themes were identified. The 19 overarching decision-making themes were integrated into a framework for quality decision-making. ConclusionThis study has achieved its aim of exploring decision-making from the perspective of the individual and the organisation working in drug development and the regulatory review and has identified issues and considerations relating to making good quality decisions and allowed for the generation of a framework to aid quality decision-making. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:319 / 328
页数:10
相关论文
共 17 条
[1]  
Bazeleys P, 2007, QUALITATIVE DATA ANA
[2]   Medicines regulation and the pharmaceutical industry [J].
Breckenridge, A ;
Woods, K .
BRITISH MEDICAL JOURNAL, 2005, 331 (7520) :834-836
[3]   A Quantitative Approach for Making Go/No-Go Decisions in Drug Development [J].
Chuang-Stein, Christy ;
Kirby, Simon ;
French, Jonathan ;
Kowalski, Ken ;
Marshall, Scott ;
Smith, Mike K. ;
Bycott, Paul ;
Beltangady, Mohan .
DRUG INFORMATION JOURNAL, 2011, 45 (02) :187-202
[4]  
Dafts R, 2005, MANAGEMENT
[5]   Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma [J].
Eichler, Hans-Georg ;
Pignatti, Francesco ;
Flamion, Bruno ;
Leufkens, Hubert ;
Breckenridge, Alasdair .
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (10) :818-826
[6]   The risks of risk aversion in drug regulation [J].
Eichler, Hans-Georg ;
Bloechl-Daum, Brigitte ;
Brasseur, Daniel ;
Breckenridge, Alasdair ;
Leufkens, Hubert ;
Raine, June ;
Salmonson, Tomas ;
Schneider, Christian K. ;
Rasi, Guido .
NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (12) :907-916
[7]  
Eichler HG, 2011, NAT REV DRUG DISCOV, V10, P495, DOI [10.1038/nrd3348, 10.1038/nrd3501]
[8]  
European Medicines Agency (EMA), 2010, DESCR BEN RISK ASS M
[9]  
Hammonds K, 1999, SMART CHOICES PRACTI
[10]  
Harriss R, 2012, INTRO DECISION MAKIN